Aducanumab for Alzheimer’s disease: A regulatory perspective

Title
Aducanumab for Alzheimer’s disease: A regulatory perspective
Authors
Keywords
Alzheimer's disease, Aducanumab, Surrogate marker, Conditional marketing approval, European Medicines Agency, Food and Drug Administration
Journal
PHARMACOLOGICAL RESEARCH
Volume 171, Issue -, Pages 105754
Publisher
Elsevier BV
Online
2021-07-02
DOI
10.1016/j.phrs.2021.105754

Ask authors/readers for more resources

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started